3 results
8-K
EX-99.1
APGE
Apogee Therapeutics Inc.
15 May 24
Regulation FD Disclosure
4:39pm
challenges, including frequent injection regimens that can lead to poor patient compliance.
“Our Phase 2 trial features an innovative design, enabling us
8-K
EX-99.2
APGE
Apogee Therapeutics Inc.
5 Mar 24
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
6:11am
progressing the rest of our pipeline forward. At Apogee, we refuse to stop at good enough and are dedicated to advancing innovative solutions … strategic collaboration with Paragon Therapeutics, Inc., an innovative discovery engine for biologics.
Key Phase 1 Interim Findings
The Phase 1 trial
8-K
EX-99.1
APGE
Apogee Therapeutics Inc.
7 Aug 23
Regulation FD Disclosure
7:35am
Therapeutics, Inc., an innovative discovery engine developing potentially best-in-class biologics
San Francisco, CA and Waltham, MA, August 7, 2023
- Prev
- 1
- Next